Amol Akhade: I-DXD shows promising activity in heavily pretreated Extensive stage SCLC
Amol Akhade shared on LinkedIn:
“I-DXD ( Ifinatamab Deruxtecan) shows promising activity in heavily pretreated Extensive stage SCLC. Impressive results from the IDeat-Lung01 phase 2 study reveal a 90.5% disease control rate with a median progression-free survival of 5.5 months and a median overall survival of 11.8 months for 12 mg per Kg dose
With patients having undergone 2 prior lines of therapy, and 76% receiving prior IO, these outcomes are significant. The Phase 3 trial, IDeat-lung 02, is currently ongoing, continuing the progress in this area.”
Read Further.
Source: Amol Akhade/LinkedIn
More posts featuring Amol Akhade on oncodaily.com
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023